GRCL
Gracell Biotechnologies Inc.
NASDAQ: GRCL · HEALTHCARE · BIOTECHNOLOGY
$10.25
+0.00% today
Updated 2026-10-29
Market cap
$989.87M
P/E ratio
—
P/S ratio
732.21x
EPS (TTM)
$-0.97
Dividend yield
—
52W range
$0 – $0
Volume
6.4M
Gracell Biotechnologies Inc. (GRCL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $366000.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | -100.0% | — |
| Cost of revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | $366000.00 | — | — |
| Gross margin | — | — | — | 100.0% | — | — |
| R&D | $52.24M | $119.22M | $168.83M | $326.90M | $485.39M | $444.51M |
| SG&A | $10.26M | $27.36M | $45.57M | $137.04M | $139.27M | $134.32M |
| Operating income | $-62.50M | $-146.58M | $-214.40M | $-463.57M | $-624.66M | $-578.83M |
| Operating margin | — | — | — | -126659.3% | — | — |
| EBITDA | $-57.80M | $-144.01M | $-202.18M | $-385.13M | $-568.67M | — |
| EBITDA margin | — | — | — | -105226.0% | — | — |
| EBIT | $-60.79M | $-146.58M | $-209.75M | $-463.57M | $-600.75M | — |
| Interest expense | $0.00 | $0.00 | $2.15M | $5.06M | $6.74M | $6.44M |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-60.79M | $-132.18M | $-197.16M | $-465.88M | $-607.51M | $-496.98M |
| Net income growth (YoY) | — | -117.4% | -49.2% | -136.3% | -30.4% | +18.2% |
| Profit margin | — | — | — | -127289.6% | — | — |
Frequently asked questions
Is GRCL's balance sheet healthy?
GRCL holds $1.45B in cash and equivalents against $46.51M in long-term debt, on $1.38B of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.